Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692011 | 0.87 | ALDH1A1 (0.37) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL20782639 | 0.84 | ALDH1A1 (0.40) | ALDH1A1LMNAALBMAPK1POLB | |
| SCHEMBL22340207 | 0.84 | POLB (0.41) | POLBIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL22340090 | 0.84 | POLB (0.44) | POLBTAS1R3TAS1R1P2RY2 | |
| SCHEMBL22340220 | 0.83 | DTYMK (0.44) | POLB | |
| SCHEMBL24060672 | 0.83 | ALDH1A1 (0.39) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL22340212 | 0.82 | DTYMK (0.42) | POLBTAS1R3TAS1R1P2RY2 | |
| SCHEMBL20692032 | 0.81 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1IMPDH2 | |
| SCHEMBL22340218 | 0.78 | IMPDH2 (0.44) | POLBIMPDH2IMPDH1TAS1R3TAS1R1 | |
| SCHEMBL23679527 | 0.77 | POLB (0.56) | ALDH1A1LMNAALBMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | ALDH1A1 917/4885LMNA 1999/4885ALB 4882/4885 |
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ALDH1A1 917/4885LMNA 1999/4885ALB 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.